| SVATON, Martin, Monika BRATOVÁ, Ondrej FISCHER, Jana KREJCI, Leona KOUBKOVA, Marketa CERNOVSKA, Michal HRNCIARIK, Milada ZEMANOVA, Helena ČOUPKOVÁ, Bedrich PORZER, Daniel DOLEZAL, Tana TUZOVA, Karolina HURDALKOVA, Magda BARINOVA a Jana SKŘIČKOVÁ. Real-life Effectiveness of Afatinib Versus Gefitinib in Patients With Non-small-cell Lung Cancer: A Czech Multicentre Study. Anticancer Research. Athens: International Institute of Anticancer Research, 2021, roč. 41, č. 4, s. 2059-2065. ISSN 0250-7005. Dostupné z: https://dx.doi.org/10.21873/anticanres.14975. |
Další formáty:
BibTeX
LaTeX
RIS
@article{1772601,
author = {Svaton, Martin and Bratová, Monika and Fischer, Ondrej and Krejci, Jana and Koubkova, Leona and Cernovska, Marketa and Hrnciarik, Michal and Zemanova, Milada and Čoupková, Helena and Porzer, Bedrich and Dolezal, Daniel and Tuzova, Tana and Hurdalkova, Karolina and Barinova, Magda and Skřičková, Jana},
article_location = {Athens},
article_number = {4},
doi = {http://dx.doi.org/10.21873/anticanres.14975},
keywords = {Afatinib; gefitinib; NSCLC; real world data},
language = {eng},
issn = {0250-7005},
journal = {Anticancer Research},
title = {Real-life Effectiveness of Afatinib Versus Gefitinib in Patients With Non-small-cell Lung Cancer: A Czech Multicentre Study},
url = {https://ar.iiarjournals.org/content/41/4/2059},
volume = {41},
year = {2021}
}
TY - JOUR
ID - 1772601
AU - Svaton, Martin - Bratová, Monika - Fischer, Ondrej - Krejci, Jana - Koubkova, Leona - Cernovska, Marketa - Hrnciarik, Michal - Zemanova, Milada - Čoupková, Helena - Porzer, Bedrich - Dolezal, Daniel - Tuzova, Tana - Hurdalkova, Karolina - Barinova, Magda - Skřičková, Jana
PY - 2021
TI - Real-life Effectiveness of Afatinib Versus Gefitinib in Patients With Non-small-cell Lung Cancer: A Czech Multicentre Study
JF - Anticancer Research
VL - 41
IS - 4
SP - 2059-2065
EP - 2059-2065
PB - International Institute of Anticancer Research
SN - 02507005
KW - Afatinib
KW - gefitinib
KW - NSCLC
KW - real world data
UR - https://ar.iiarjournals.org/content/41/4/2059
N2 - Background/Aim: We investigated efficacy differences for afatinib versus gefitinib in non-small-cell lung cancer (NSCLC) according to epidermal growth factor receptor (EGFR) mutations. Patients and Methods: We retrospectively analysed data for 343 patients with NSCLC with performance status 1 having EGFR mutations treated with gefitinib or afatinib. Overall response rate (ORR) was tested by Fisher & rsquo;s exact test. Overall (OS) and progression free (PFS) survival were estimated by Kaplan & ndash;Meier method. Results: ORR did not differ in any group or subgroup. Among all patients, we observed significantly longer PFS for those treated with afatinib vs. gefitinib (median 13.4 vs. 9.5 months, p=0.026), but only a nonsignificant trend was observed for OS. We showed nonsignificant trends of better PFS and OS using afatinib for exon 19 deletion and L858R subgroups. We observed no significant PFS differences for other EGFR mutations but a nonsignificant trend towards better OS for those treated with afatinib. Conclusion: Afatinib led to longer PFS for patients with common EGFR mutations but not for those with rare mutations.
ER -
SVATON, Martin, Monika BRATOVÁ, Ondrej FISCHER, Jana KREJCI, Leona KOUBKOVA, Marketa CERNOVSKA, Michal HRNCIARIK, Milada ZEMANOVA, Helena ČOUPKOVÁ, Bedrich PORZER, Daniel DOLEZAL, Tana TUZOVA, Karolina HURDALKOVA, Magda BARINOVA a Jana SKŘIČKOVÁ. Real-life Effectiveness of Afatinib Versus Gefitinib in Patients With Non-small-cell Lung Cancer: A Czech Multicentre Study. \textit{Anticancer Research}. Athens: International Institute of Anticancer Research, 2021, roč.~41, č.~4, s.~2059-2065. ISSN~0250-7005. Dostupné z: https://dx.doi.org/10.21873/anticanres.14975.
|
